基于NIA-AA研究框架的生物学与临床定义阿尔茨海默谱系实体患病率比较
该研究基于梅奥诊所老龄化研究队列,估计了NIA-AA研究框架下三种影像学生物标志物定义的阿尔茨海默谱系实体的性别和年龄别患病率,并与临床诊断组比较。结果显示,生物学定义的阿尔茨海默病患病率在任何年龄均高于临床可能阿尔茨海默病,在85岁时约为后者的3倍,且差异主要由无症状的生物学阿尔茨海默病患者驱动。
要点
- 生物学定义的阿尔茨海默病在70岁和85岁患病率均显著高于临床可能阿尔茨海默病。
- 85岁时生物学阿尔茨海默病患病率约为临床可能阿尔茨海默病的3倍。
- 患病率差异主要由无症状的生物学阿尔茨海默病患者驱动。
核心结论
- 生物学定义的阿尔茨海默病在任何年龄均比临床可能阿尔茨海默病更常见,85岁时约为后者的3倍。
- 该差异主要由无症状的生物学阿尔茨海默病患者驱动。
研究设计与样本
- 梅奥诊所老龄化研究为基于人群的队列研究,纳入60至89岁面对面参与者(n=4660)和被动确认的痴呆患者(n=553)。
- 子集分别接受淀粉样蛋白PET(n=1524)或淀粉样蛋白和tau PET(n=576),共三个嵌套队列于2004年11月29日至2018年6月5日期间检查。
主要发现
- 临床队列(n=5213)中位年龄77(IQR 72-83)岁,淀粉样蛋白PET队列(n=1524)中位年龄77(IQR 70-83)岁,tau PET队列(n=576)中位年龄77(IQR 69-83)岁,男女数量大致相等。
- 除阿尔茨海默病理改变外,所有诊断实体(生物学和临床)的患病率均随年龄迅速增加。
- 女性中,生物学阿尔茨海默病与临床可能阿尔茨海默病患病率在70岁时为10%(95%CI 6%-14%) vs 1%(95%CI 1%-1%),在85岁时为33%(95%CI 25%-41%) vs 10%(95%CI 9%-12%)(P<.001)。
- 男性中,相应值在70岁时为9%(95%CI 5%-12%) vs 1%(95%CI 0%-1%),在85岁时为31%(95%CI 24%-38%) vs 9%(95%CI 8%-11%)(P<.001)。
- 性别间唯一显著差异是男性轻度认知障碍或痴呆临床类别患病率高于女性。
关键数值与推荐
- 生物学定义实体包括阿尔茨海默连续体(淀粉样蛋白异常,无论tau状态)、阿尔茨海默病理改变(淀粉样蛋白异常但tau正常)和阿尔茨海默病(淀粉样蛋白和tau均异常)。
- 临床定义组包括轻度认知障碍或痴呆、痴呆和临床可能阿尔茨海默病。
临床怎么用
- 提示临床实践中应关注生物学定义的阿尔茨海默病在无症状个体中的高患病率,对公共卫生和疾病特异性治疗干预有潜在影响。
局限性
- 研究仅基于梅奥诊所老龄化研究队列,外推性可能受限。
- 仅部分参与者接受了淀粉样蛋白PET或tau PET,存在选择偏倚可能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: A National Institute on Aging-Alzheimer's Association (NIA-AA) workgroup recently published a research framework in which Alzheimer disease is defined by neuropathologic or biomarker evidence of β-amyloid plaques and tau tangles and not by clinical symptoms. OBJECTIVES: To estimate the sex- and age-specific prevalence of 3 imaging biomarker-based definitions of the Alzheimer disease spectrum from the NIA-AA research framework and to compare these entities with clinically defined diagnostic entities commonly linked with Alzheimer disease. DESIGN, SETTING, AND PARTICIPANTS: The Mayo Clinic Study of Aging (MCSA) is a population-based cohort study of cognitive aging in Olmsted County, Minnesota. The MCSA in-person participants (n = 4660) and passively ascertained (ie, through the medical record rather than in-person) individuals with dementia (n = 553) aged 60 to 89 years were included. Subsets underwent amyloid positron emission tomography (PET) (n = 1524) or both amyloid and tau PET (n = 576). Therefore, this study included 3 nested cohorts examined between November 29, 2004, and June 5, 2018. Data were analyzed between February 19, 2018, and March 26, 2019. MAIN OUTCOMES AND MEASURES: The sex- and age-specific prevalence of the following 3 biologically defined diagnostic entities was estimated: Alzheimer continuum (abnormal amyloid regardless of tau status), Alzheimer pathologic change (abnormal amyloid but normal tau), and Alzheimer disease (abnormal amyloid and tau). These were compared with the prevalence of 3 clinically defined diagnostic groups (mild cognitive impairment or dementia, dementia, and clinically defined probable Alzheimer disease). RESULTS: The median (interquartile range) age was 77 (72-83) years in the clinical cohort (n = 5213 participants), 77 (70-83) years in the amyloid PET cohort (n = 1524 participants), and 77 (69-83) years in the tau PET cohort (n = 576 participants). There were roughly equal numbers of women and men. The prevalence of all diagnostic entities (biological and clinical) increased rapidly with age, with the exception of Alzheimer pathologic change. The prevalence of biological Alzheimer disease was greater than clinically defined probable Alzheimer disease for women and men. Among women, these values were 10% (95% CI, 6%-14%) vs 1% (95% CI, 1%-1%) at age 70 years and 33% (95% CI, 25%-41%) vs 10% (95% CI, 9%-12%) at age 85 years (P < .001). Among men, these values were 9% (95% CI, 5%-12%) vs 1% (95% CI, 0%-1%) at age 70 years and 31% (95% CI, 24%-38%) vs 9% (95% CI, 8%-11%) at age 85 years (P < .001). The only notable difference by sex was a greater prevalence of the mild cognitive impairment or dementia clinical category among men than women. CONCLUSIONS AND RELEVANCE: Results of this study suggest that biologically defined Alzheimer disease is more prevalent than clinically defined probable Alzheimer disease at any age and is 3 times more prevalent at age 85 years among both women and men. This difference is mostly driven by asymptomatic individuals with biological Alzheimer disease. These findings illustrate the magnitude of the consequences on public health that potentially exist by intervening with disease-specific treatments to prevent symptom onset.
引用
- Jack CR, Therneau TM, Weigand SD, et al. Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National Institute on Aging-Alzheimer's Association Research Framework. JAMA Neurol. 2019. PMID: 31305929. doi:10.1001/jamaneurol.2019.1971
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。